Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cytarabine
Drug ID BADD_D00560
Description A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Indications and Usage For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Marketing Status Prescription; Discontinued
ATC Code L01BC01
DrugBank ID DB00987
KEGG ID D00168
MeSH ID D003561
PubChem ID 6253
TTD Drug ID D07XSN
NDC Product Code 67457-452; 68083-343; 58623-0026; 68083-337; 67457-455; 71288-108; 61703-303; 70516-0163; 71288-109; 61703-319; 63323-120; 71288-169; 61703-305; 71288-168; 55512-0026; 61703-304; 12848-1003
Synonyms Cytarabine | Arabinosylcytosine | Cytosine Arabinoside | Arabinoside, Cytosine | Arabinofuranosylcytosine | Aracytidine | beta-Ara C | beta Ara C | Cytarabine Hydrochloride | Cytosar | Cytosar-U | Cytosar U | Ara-C | Ara C | Aracytine | Cytonal
Chemical Information
Molecular Formula C9H13N3O5
CAS Registry Number 147-94-4
SMILES C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal adhesions07.07.03.001; 12.02.03.0060.000533%Not Available
Abdominal distension07.01.04.0010.001332%
Abdominal pain07.01.05.0020.005062%
Abdominal pain upper07.01.05.003--
Abdominal tenderness07.01.05.0040.000533%Not Available
Abscess11.01.08.0010.001066%Not Available
Acidosis14.01.03.0020.001332%
Acute febrile neutrophilic dermatosis01.02.01.006; 23.03.03.0330.002398%Not Available
Acute hepatic failure09.01.03.0010.000486%Not Available
Acute leukaemia01.10.02.001; 16.01.02.0010.000533%Not Available
Acute myeloid leukaemia01.10.05.001; 16.01.05.0010.001876%Not Available
Acute myocardial infarction02.02.02.001; 24.04.04.0010.001066%Not Available
Acute respiratory distress syndrome22.01.03.0010.002363%
Acute respiratory failure14.01.04.004; 22.02.06.0010.000973%Not Available
Adrenal insufficiency05.01.02.001; 14.11.01.0040.001066%
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.0010.001332%Not Available
Alanine aminotransferase increased13.03.01.003--
Alopecia23.02.02.001--
Anaemia01.03.02.0010.004263%
Anaemia megaloblastic01.03.02.003; 14.12.01.003--Not Available
Anal fistula07.11.05.0020.000799%
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Angina pectoris02.02.02.002; 24.04.04.0020.000533%
Anuria20.01.03.0020.000533%Not Available
Aplasia03.02.01.002; 08.03.04.0030.000347%Not Available
Appendicitis07.19.01.001; 11.01.07.0010.000799%
Arrhythmia02.03.02.0010.000799%Not Available
Arteriosclerosis coronary artery02.02.01.011; 24.04.04.0120.000139%Not Available
Arthralgia15.01.02.001--
The 1th Page    1 2 3 4 5    Next   Last    Total 17 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene